세계의 동물 표준 실험실 시장은 2024년에는 49억 달러로 평가되었고 CAGR 10.6%로 성장하여 2034년에는 133억 달러에 이를 것으로 추정됩니다.
성장의 주된 원동력은 가축이나 반려동물의 만성 질환이나 인수 공통 감염증의 이환율의 상승입니다.
동물의 건강 관리를 개선하는 것을 중심으로 한 규제의 대처에 추진된 민관 투자가 진단 인프라의 정비에 박차를 가하고 있습니다. 시장에도 서비스가 확산되고 있으며, 반려동물 보험 가입률 상승으로 반려동물 주인에게 수의학적 진단이 보다 경제적으로 이용하기 쉬워지고 있습니다. 또한 기준 시설 서비스의 이용이 촉진되어 선진 경제 국가와 신흥 경제 국가 모두에서 시장의 규모가 확대되고 있습니다.
| 시장 범위 | |
|---|---|
| 시작 연도 | 2024년 |
| 예측 연도 | 2025-2034년 |
| 시작 금액 | 49억 달러 |
| 예측 금액 | 133억 달러 |
| CAGR | 10.6% |
2024년, 임상 화학 분야는 18억 달러의 평가액을 달성했습니다. 화학 검사는 당뇨병, 내분비 질환과 같은 만성 질환의 검출에 특히 적합합니다.
임상 병리 부문은 2024년에 34.6%의 점유율을 획득했으며, 여전히 동물용 진단의 핵심 요소로 이용되고 있습니다. 최우선적인 동물 건강 평가방식으로 일상적인 건강 모니터링부터 복잡한 질병의 진단에 이르기까지 모든 상황에서 유용합니다.
미국 동물 표준 실험실 시장은 2024년에 17억 달러에 이르렀습니다. 수의학 인프라는 반려동물 보험의 보급과 함께 보다 잦은 진단 검사를 촉구하고 있습니다.
세계 동물 표준 실험실 시장에서 사업을 전개하는 주요 기업은 Zoetis, Heska Corporation, IDEXX Laboratories, Thermo Fisher Scientific, Antech Diagnostics(Mars), Virbac, Nova Biomedical, Vaxxinova, Boehringer Health, Neogen Corporation, Colorado State University 등이 있습니다. 많은 기업들은 보다 신속하고 정확한 결과를 제공하기 위해 차세대 진단 툴과 자동화에도 투자하고 있습니다.
The Global Veterinary Reference Laboratory Market was valued at USD 4.9 billion in 2024 and is estimated to grow at a CAGR of 10.6% to reach USD 13.3 billion by 2034. A major driver of this growth is the rising incidence of chronic and zoonotic diseases in farm and companion animals. This increase in disease burden has sparked greater demand for diagnostic services, especially as awareness among pet owners regarding early diagnosis of conditions like diabetes, cancer, and parasitic infections continues to grow. In the livestock industry, stricter requirements around food safety and animal health are further encouraging the adoption of advanced testing services.
Public and private investments, driven by regulatory efforts centered on improving animal health management, are fueling the development of diagnostic infrastructure. Expanding networks of veterinary diagnostic laboratories and growing collaborations between clinics and reference facilities are helping to extend services into previously underserved markets. Additionally, a rise in pet insurance coverage is making veterinary diagnostics more financially accessible to pet owners, enhancing the utilization of reference laboratory services and accelerating the market's momentum across both developed and emerging economies.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $4.9 Billion |
| Forecast Value | $13.3 Billion |
| CAGR | 10.6% |
In 2024, the clinical chemistry segment achieved a valuation of USD 1.8 billion due to the critical role these tests play in analyzing blood and bodily fluids. These tests are essential for assessing internal organ functions, electrolyte levels, and overall metabolic status. They are particularly relevant for detecting chronic diseases such as renal disorders, diabetes, and endocrine conditions in pets and livestock. The growing use of automated, high-throughput analyzers in reference labs has helped deliver quick and accurate results, meeting the increasing demand for both routine and emergency diagnostic services.
The clinical pathology segment captured a 34.6% share in 2024 and remains a cornerstone of veterinary diagnostics. This category includes vital services like hematology, cytology, urinalysis, and chemistry-based tests that help identify various disease conditions in animals. Clinical pathology serves as the first line of evaluation in veterinary healthcare, aiding in everything from routine health monitoring to diagnosing complex illnesses. With chronic and infectious diseases becoming more common, there is heightened reliance on these tests for managing animal health across both clinical and preventive care settings.
U.S. Veterinary Reference Laboratory Market reached USD 1.7 billion in 2024. Its growth is driven by high pet ownership rates, increasing veterinary expenditures, and strong access to modern animal care services. The country's well-established veterinary infrastructure, along with the widespread adoption of pet insurance, is encouraging more frequent diagnostic testing. This environment supports the expansion of advanced reference laboratory services in the country and contributes significantly to the overall market.
Key players operating in the Global Veterinary Reference Laboratory Market include Zoetis, Heska Corporation, IDEXX Laboratories, Thermo Fisher Scientific, Antech Diagnostics (Mars), Virbac, Nova Biomedical, Vaxxinova, Boehringer Ingelheim International, Laboklin, GD Animal Health, Neogen Corporation, and Colorado State University. To strengthen their position in the veterinary reference laboratory market, companies are implementing a range of strategic initiatives. These include expanding their laboratory networks and entering strategic partnerships with veterinary clinics to boost service accessibility. Many firms are also investing in next-generation diagnostic tools and automation to deliver faster, more accurate results. Emerging markets through acquisitions and localized service offerings, allowing them to reach more customers while enhancing operational scalability.